A subgroup of GBM is characterized by high expression levels of MYC and MYCN genes, indicating their potential as therapeutic targets in GBM.24 The identification of MYC as a hub in the protein-protein interaction network suggests its central role in GBM pathogenesis. The gene discussed is MYCN; the disease is glioblastoma.